Lonza Group AG (ETR:LO3)

Market Cap	43.04B
Revenue (ttm)	7.01B
Net Income (ttm)	677.91M
Shares Out	n/a
EPS (ttm)	9.51
PE Ratio	63.48
Forward PE	34.63
Dividend	4.27 (0.71%)
Ex-Dividend Date	May 13, 2025

Volume	80
Average Volume	25
Open	609.00
Previous Close	597.80
Day's Range	608.80 - 611.60
52-Week Range	592.40 - 643.80
Beta	n/a
RSI	50.95
Earnings Date	Jul 23, 2025

About Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substanc...

• Industry: Other
• Founded: 1897
• Employees: 18,944
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: LO3

Financial Performance

In 2024, Lonza Group AG's revenue was 6.57 billion, a decrease of -2.13% compared to the previous year's 6.72 billion. Earnings were 636.00 million, a decrease of -2.75%.

Financial numbers in CHF